Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer

Bahriye Aktas; Tanja N. Fehm; Manfred Welslau; Volkmar Müller; Diana Lüftner; Florian Schütz; Peter A. Fasching; Wolfgang Janni; Christoph Thomssen; Isabell Witzel; Erik Belleville; Michael Untch; Marc Thill; Hans Tesch; Nina Ditsch; Michael P. Lux; Maggie Banys-Paluchowski; Cornelia Kolberg-Liedtke; Andreas D. Hartkopf; Achim Wöckel; Hans-Christian Kolberg; Elmar Stickeler; Nadia Harbeck; Andreas Schneeweiss

doi:10.1055/a-1912-7362

Geburtshilfe und Frauenheilkunde, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2022; 82(09): 922-931
DOI: 10.1055/a-1912-7362

GebFra Science

Review/Übersicht

Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer

Artikel in mehreren Sprachen: English | deutsch

Autor*innen

Bahriye Aktas

¹Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
Tanja N. Fehm

²Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
Manfred Welslau

³Onkologie Aschaffenburg, Aschaffenburg, Germany
Volkmar Müller

⁴Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
Diana Lüftner

⁵Immanuel Hospital Märkische Schweiz & Medical University of Brandenburg Theodor-Fontane, Brandenburg, Buckow, Germany
Florian Schütz

⁶Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany
Peter A. Fasching

⁷Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Wolfgang Janni

⁸Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
Christoph Thomssen

⁹Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
Isabell Witzel

⁴Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
Erik Belleville

¹⁰ClinSol GmbH & Co KG, Würzburg, Germany
Michael Untch

¹¹Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
Marc Thill

¹²Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main, Germany
Hans Tesch

¹³Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
Nina Ditsch

¹⁴Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
Michael P. Lux

¹⁵Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Germany
Maggie Banys-Paluchowski

¹⁶Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
Cornelia Kolberg-Liedtke

¹⁷Department of Gynecology and Obstetrics, University Hospital Essen, Essen, Germany
Andreas D. Hartkopf

⁸Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
Achim Wöckel

¹⁸Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
Hans-Christian Kolberg

¹⁹Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
Elmar Stickeler

²⁰Department of Gynecology and Obstetrics, RWTH University Hospital Aachen, Aachen, Germany
Nadia Harbeck

²¹Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
Andreas Schneeweiss

²²National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

Abstract

For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors – trastuzumab deruxtecan, sacituzumab govitecan and capivasertib – is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification.

Key words

advanced breast cancer - chemotherapy - endocrine therapy - antibody drug conjugates

Volltext

Referenzen

References/Literatur
1 Wolff AC, Hammond MEH, Allison KH. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018; 36: 2105-2122
2 Ahmed N, Brawley VS, Hegde M. et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol 2015; 33: 1688-1696
3 Burger MC, Zhang C, Harter PN. et al. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Front Immunol 2019; 10: 2683
4 Erber R, Kailayangiri S, Huebner H. et al. Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers (Basel) 2021; 13: 5577
5 Yu AL, Gilman AL, Ozkaynak MF. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-1334
6 Bardia A, Hurvitz SA, Tolaney SM. et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384: 1529-1541
7 Thill M, Friedrich M, Kolberg-Liedtke C. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16: 228-235
8 Schneeweiss A, Ettl J, Luftner D. et al. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54: 88-95
9 Engler T, Fasching PA, Lüftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022;
10 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022;
11 Baselga J, Im SA, Iwata H. et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 904-916
12 Andre F, Ciruelos E, Rubovszky G. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940
13 Vanhaesebroeck B, Perry MWD, Brown JR. et al. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov 2021; 20: 741-769
14 Vasan N, Cantley LC. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol 2022; 19: 471-485
15 Jones RH, Casbard A, Carucci M. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2020; 21: 345-357
16 Jones RH, Casbard AC, Carucci M. et al. Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis. J Clin Oncol 2022; 40: 1005
17 clinicaltrials.gov. Capivasertib+Fulvestrant vs. Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291). 2022. Accessed June 27, 2022 at: https://clinicaltrials.gov/ct2/show/NCT04305496
18 clinicaltrials.gov. Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292). (CAPItello-292). 2022. Accessed June 27, 2022 at: https://clinicaltrials.gov/ct2/show/NCT04862663
19 Neven P, Fasching PA, Chia S. et al. Updated overall survival (OS) results from the first-line (1 L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Ann Oncol 2022; 33 (Suppl. 03) S194-S223
20 Hortobagyi GN, Stemmer SM, Burris HA. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950
21 Finn RS, Rugo HS, Dieras VC. et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. J Clin Oncol 2022; 40: LBA1003
22 Bidard F, Hardy-Bessard A, Bachelot T. et al. Fulvestrant-palbociclib vs. continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial. San Antonio Breast Cancer Symposium 2021; 2021: GS3-05
23 clinicaltrials.gov. Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA). 2022. Accessed June 26, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05362760
24 Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 2018; 9: 28989-29006
25 Zaman S, Jadid H, Denson AC. et al. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther 2019; 12: 1781-1790
26 Vranic S, Gatalica Z. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers. Bosn J Basic Med Sci 2022; 22: 14-21
27 Liu X, Zhou T, Wang Y. et al. TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer. Onco Targets Ther 2022; 15: 509-520
28 Hurvitz SA, Tolaney SM, Punie K. et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2020; 2020: GS3-06
29 Rugo HS, Bardia A, Marmé F. et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physicianʼs choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol 2022; 40: LBA1001
30 Clinicaltrials.gov. Study of Trastuzumab Deruxtecan (T-DXd) vs. Investigatorʼs Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06). 2022. Accessed June 26, 2022 at: https://clinicaltrials.gov/ct2/show/NCT04494425
31 clinicaltrials.gov. Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1 m Before Progression (SERENA-6) (SERENA-6). 2021. Accessed October 24, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04964934
32 clinicaltrials.gov. Comprehensive Analysis of Spatial, Temporal and Molecular Patters of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC). 2022. Accessed July 16, 2022 at: https://clinicaltrials.gov/ct2/show/NCT05452213
33 Fasching PA. CAPTOR-BC: Gemeinsam Forschen für eine individualisierte Ribociclib-Therapie Senologiekongress 2022. 2022. Accessed June 26, 2022 at: https://www.senologiekongress.de/xconfig/upload/files/Programme/Seno2022_Programm.pdf
34 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748
35 European Medicines Agency. Verzenios Summary of product characteristics (SmPC). 2022. Accessed March 26, 2022 at: https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_de.pdf
36 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646
37 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936
38 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
39 Tripathy D, Im S-A, Colleoni M. et al. Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Res 2021; 81: PD2-04-PD02-04
40 Tripathy D, Im SA, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;
41 Fasching PA, Esteva FJ, Pivot X. et al. Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3. Ann Oncol 2018; 29: viii90-viii121
42 Slamon DJ, Neven P, Chia S. et al. Overall Survival Results from the Phase 3 MONALEESA-3 Study of Fulvestrant ± Ribociclib in Postmenopausal Patients With HR+/HER2− Advanced Breast Cancer. Ann Oncol 2019; 30 (Suppl. 05) v851-v934
43 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
44 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472
45 Sledge jr. GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2020; 6: 116-124
46 Sledge jr. GW, Toi M, Neven P. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35: 2875-2884
47 Cristofanilli M, Rugo HS, Im S-A. et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. J Clin Oncol 2021; 39: 1000
48 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
49 Turner NC, Slamon DJ, Ro J. et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936
50 Xu B, Zhang Q, Zhang P. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med 2021; 27: 1904-1909
51 Hein A, Hartkopf AD, Emons J. et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer 2021; 155: 1-12
52 Guyot P, Ades AE, Ouwens MJ. et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012; 12: 9
53 Yi Z, Ma F. Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer. J Breast Cancer 2017; 20: 321-326